Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection

Camille M. Webb, Miguel M. Cabada

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Purpose of reviewThis review aims at describing the latest research in Fasciola epidemiology, diagnosis, treatment, and control in endemic countries.Recent findingsThe geographic distribution and range of reservoirs for Fasciola hepatica continues to expand. The impact of fascioliasis goes beyond human disease to affect food security and income in developed and developing countries. Promising serologic and molecular methods to diagnose fascioliasis have been described, but are not widely available. Triclabendazole remains the only highly active medication to treat human and livestock infected with juvenile and adult forms of Fasciola spp. Efforts to control fascioliasis may be hindered by the emergence of resistance to triclabendazole among livestock and subsequently in humans.SummaryIncreased awareness and surveillance are likely to uncover the real distribution and burden of fascioliasis in human. Research into new drugs or adjuvants to tackle the emerging resistance to triclabendazole is imperative to treat and control Fasciola infection.

Original languageEnglish (US)
Pages (from-to)409-414
Number of pages6
JournalCurrent opinion in infectious diseases
Issue number5
StatePublished - Oct 1 2018


  • Fasciola hepatica
  • burden
  • control
  • triclabendazole

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection'. Together they form a unique fingerprint.

Cite this